A new publication involving MOTS-c appeared on September 21, 2026. The paper, titled "MOTS-c mediates remote ischemic preconditioning-induced protection against lung ischemia-reperfusion injury via NRF2-dependent mitochondrial biogenesis," was published in Chinese Medical Journal.
The title indicates the study examines MOTS-c in the context of remote ischemic preconditioning and lung ischemia-reperfusion injury, with reference to NRF2-dependent mitochondrial biogenesis. This brief reports only the publication event, including its title, journal, and date, as provided.
No specific findings, data, or conclusions from the study are described here beyond what is stated in the title itself. MOTS-c remains classified as an unapproved compound used in research settings. Readers interested in the details of the study's methods and results should consult the original publication directly through the listed source.
For general background on this compound, readers can refer to the compound overview.